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BACKGROUND: Major bleeding after acute coronary syndrome predicts a poor outcome but is challenging to define. The choice 
of antiplatelet influences bleeding risk.
METHODS AND RESULTS: Major bleeding, subsequent myocardial infarction (MI), and all- cause mortality to 1 year were compared 
in consecutive patients with acute coronary syndrome treated with clopidogrel (n=2491 between 2011 and 2013) and ticagrelor 
(n=2625 between 2012 and 2015) in 5 English hospitals. Clinical outcomes were identified from national hospital episode statis-
tics. Bleeding and MI events were independently adjudicated by 2 experienced clinicians, blinded to drug, sequence, and year. 
Bleeding events were categorized using Bleeding Academic Research Consortium 3 to 5 and PLATO (Platelet Inhibition and Patient 
Outcomes) criteria and MI by the Third Universal Definition. Multivariable regression analysis was used to adjust outcomes for case 
mix. The median age was 68 years and 34% were women. 39% underwent percutaneous coronary intervention and 13% coronary 
artery bypass graft surgery. Clinical outcome data were 100% complete for bleeding and 99.7% for MI. No statistically significant 
difference was seen in crude or adjusted major bleeding for ticagrelor compared with clopidogrel (Bleeding Academic Research 
Consortium 3– 5, hazard ratio [HR], 1.23; 95% CI, 0.90– 1.68; P=0.2, PLATO major adjusted HR, 1.30; 95% CI, 0.98– 1.74; P=0.07) 
except in the non- coronary artery bypass graft cohort (n=4464), where bleeding was more frequent with ticagrelor (Bleeding 
Academic Research Consortium 3– 5, adjusted HR, 1.58; 95% CI, 1.09– 2.31; P=0.017; and PLATO major HR, 1.67; 95% CI, 1.18– 
2.37; P=0.004). There was no difference in crude or adjusted subsequent MI (adjusted HR, 1.20; 95% CI, 0.87– 1.64; P=0.27). Crude 
mortality was higher in the clopidogrel group but not after adjustment, using either Cox proportional hazards or propensity matched 
population (HR, 0.90; 95% CI, 0.76– 1.10; P=0.21) as was the case for stroke (HR, 0.82; 95% CI, 0.52– 1.32; P=0.42).
CONCLUSIONS: This observational study indicates that the apparent benefit of ticagrelor demonstrated in a clinical trial popula-
tion may not be observed in the broader population encountered in clinical practice.
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Clopidogrel had been the antiplatelet of choice to be used in combination with aspirin following acute coronary syndrome (ACS).1 However, its 
poor oral bioavailability and large interindividual dif-
ferences in platelet inhibition led to development of 
newer antiplatelet agents.2 Ticagrelor is a novel non- 
thienopyridine P2Y12 inhibitor that has gained ap-
proval on the overall net or positive outcomes from 
the PLATO (Platelet Inhibition and Patient Outcomes) 
study.3 A benefit of ticagrelor over clopidogrel was 
observed in ischemic end points and all- cause death 
with similar rates of major bleeding (the risk of non- 
coronary artery bypass graft (CABG) related major 
bleeding [PLATO criteria] was increased with ticagre-
lor: 4.5% versus 3.8%, P=0.03). Following the PLATO 
trial, ticagrelor replaced clopidogrel as first- line therapy 
for many centers in the United Kingdom and Europe. 
It should be noted that the median age in the study 
was 62  years, with only 15% of patients being older 
than 75, <30% being women and <5% suffering with 
chronic renal disease. Age, female sex, and renal dys-
function are all factors associated with bleeding that 
are markedly more prevalent in populations with ACS 
in clinical practice.4– 8 Despite these differences be-
tween clinical practice and randomized clinical trials, 
the major bleeding event rate in PLATO was unusually 
high for any study of antiplatelets in ACS.3,9,10 For these 
reasons, it is conceivable that the net clinical benefit of 
ticagrelor compared with clopidogrel seen in PLATO 
may be less marked in real world populations. As far 
as we are aware no large- scale multicenter studies in 
clinical practice have used internationally accepted 
standardized definitions of bleeding, thus limiting their 
applicability. Additionally, there is very little evidence 
of outcomes in those managed with medical therapy 
without coronary revascularization.
We aimed to evaluate the impact of ticagrelor 
compared with clopidogrel for the treatment of ACS 
in a national study of clinical practice, including pa-
tients treated with medical therapy alone, in terms of 




As secondary analyses are in progress, data collected 
for the study, including individual participant data and 
a data dictionary defining each field, will not be made 
available for at least 6 months from publication.
Study Design
We selected consecutive patients treated with tica-
grelor for ACS in 5 large hospitals in the northwest 
of England for inclusion. All 5 hospitals are linked 
to a cardiothoracic center where percutaneous in-
tervention and coronary artery bypass surgery are 
performed. There was a gradual transition in the re-
gion as each hospital moved from clopidogrel paired 
with aspirin to ticagrelor with aspirin for the manage-
ment of ACS between 2012 to 2013. Consecutive pa-
tients after this transition who were diagnosed with 
ACS (ST- segment– elevation MI, non- ST- segment– 
elevation MI, or unstable angina) and treated with 
new drug prescriptions for ticagrelor (2012– 2015) 
were identified using MINAP (Myocardial Infarction 
National Audit Programme), a prospectively col-
lected national database.11 Demographic, laboratory, 
and echocardiographic data from each admission 
were obtained from clinical notes and the MINAP 
database. An identical process, but retrospectively 
in a reverse time order fashion, was undertaken to 
gather a cohort of the same size comprising consec-
utive patients treated with clopidogrel following an 
ACS immediately before the transition (2011– 2013). 
CLINICAL PERSPECTIVE
What Is New?
• In this national multicenter study of clinical prac-
tice, using adjudicated internationally recog-
nized end points for myocardial infarction and 
bleeding, we have demonstrated no improve-
ment in vascular events in the global popula-
tion but a hazard for major bleeding in patients 
medically treated with ticagrelor compared with 
clopidogrel.
What Are the Clinical Implications?
• The benefits of potent antiplatelets on vascular 
events in clinical practice appear blunted. The 
risk: benefit ratio in patients in medically treated 
acute coronary syndrome does not favor potent 
antiplatelets and should influence treatment 
decisions.
• Understanding balance of risk between subse-
quent myocardial infarction and major bleeding 
is important and requires further research in 
clinical practice and particularly in patients with 
acute coronary syndrome who do not undergo 
coronary revascularization.
Nonstandard Abbreviations and Acronyms
BARC Bleeding Academic Research Consortium
HES hospital episode statistics
MINAP  Myocardial Infarction National Audit 
Programme
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Inclusion criteria were any patient in the specified 
time period treated for ACS, as identified by MINAP, 
with either clopidogrel (before the guideline transition 
date in each individual hospital) or ticagrelor (after the 
respective transition date). Exclusion criteria included 
patients already established on the prescribed an-
tiplatelet agent before the ACS event, those under 
18 years of age, and patients treated with clopidogrel 
in the ticagrelor “era.” A full list of the inclusion and 
exclusion criteria can be found in Table S1.
Outcome Measures
The primary outcome measure was defined as major 
bleeding at 12  months, reported by both Bleeding 
Academic Research Consortium (BARC) 3 to 5 
and PLATO major bleeding definitions.3,12 The sec-
ondary outcome measures were all- cause death at 
12 months, subsequent MI, and stroke at 12 months. 
We also a priori wished to study subsets of patients 
undergoing revascularization versus those treated 
medically.
Follow- up was censored 14  days after discontin-
uation of the antiplatelet drug if this occurred before 
the 12- month period had elapsed. Follow- up was also 
censored 14 days after all CABG operations. This was 
to mitigate bias and crossover based on local surgical 
practice during the study period where most patients 
were routinely prescribed clopidogrel post- CABG. 
Outcome measures were assessed in a time to first 
event analysis, although this was treated as event/
definition specific. For example, a patient first having a 
major bleed by PLATO criteria but not meeting BARC 
criteria would remain under follow- up for the possibility 
of a BARC major bleed.
For screening of potential outcome events and ad-
judication of clinical outcomes— see Data S1, Table S2.
Ethics
This article conforms to the International Committee 
of Medical Journal Editors Recommendations for 
the Conduct, Reporting, Editing, and Publication of 
Scholarly Work in Medical Journals.
The project was registered with the research de-
partment of each of the participating 6 hospitals. Each 
hospital granted consent to undertake this study. 
Research ethics approval was also gained (National 
Research Ethics Service Committee Northwest, REC 
reference:14/NW/1326). In view of the requirement to 
obtain identifiable data without explicit patient con-
sent, approval was secured from the Health Research 
Authority Confidential Advisory Group (CAG, ref: 15/
CAG/0134). This allowed access to data from any na-
tional hospital in England. The protocol was also pro-
duced in conjunction with and approved by a regional 
patient advocacy group (SURE group, Liverpool Heart 
and Chest Hospital).
Power Calculation
The study was powered on the anticipated difference 
in bleeding rates between clopidogrel and ticagrelor. 
The expected rate of bleeding in the clopidogrel group 
is 5%, based on the balance of existing studies.1,3,9 
At a power of 80% using a significance level of 5% 
to detect a relative risk of 1.4 the study required 2210 
patients per group. Allowing for 10% loss to follow- up, 
this would require 2456 patients per group to detect a 
relative risk increase of 40% with ticagrelor compared 
with clopidogrel. We therefore aimed to include at least 
5000 consecutively treated patients, with ≈2500 in 
each group.
Statistical Analysis
Continuous variables are presented as median (with 
25th and 75th percentile) with comparisons made 
using the Wilcoxon rank sum test. Categorical vari-
ables are shown as frequency and percentages with 
comparisons made using χ2 tests or the Fisher’s exact 
test as appropriate.
To adjust for differences in baseline characteris-
tics, we generated multilevel Cox proportional haz-
ards models for each of the primary and secondary 
outcomes. Log- normal frailty survival models were 
constructed, with the clustered hospital effect incor-
porated as independent and identically distributed ran-
dom variables. Variable selection for each model was 
undertaken using a combination of stepwise selection 
and assessment of the Akaike information criterion 
(lower values indicate a better fit) before fitting the final 
random effects models.
Unadjusted and adjusted hazard ratios (HR) and 
95% CI are reported for each outcome. Intrarater 
agreement was calculated using the Cohen kappa 
statistic.13
In all cases P<0.05 was considered significant. The 
analysis was carried out using the SAS system for 
Windows v9.3 (SAS Institute, Cary, NC).
RESULTS
Figure 1 outlines the process used to identify partici-
pants for inclusion in the study. Duplicated entries and 
participants with multiple entries and follow- up periods 
crossing over led to exclusion of 109 patients. The final 
cohort consisted of 5116 individual consecutive pa-
tients with ACS.
The median age was 68  years (interquartile range 
57– 78, 30.5% over 75 years) and 34% were women. 
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treatment by percutaneous coronary intervention (PCI) 
in 39% and CABG in 13%.
Table  1 describes the overall patient population 
split by P2Y12 inhibitor. Patients in the clopidogrel 
arm were significantly older, with a greater propor-
tion of women and with lower estimated glomer-
ular filtration rate. Scores on the Can Rapid Risk 
Stratification of Unstable Angina Patients Suppress 
Adverse Outcomes With Early Implementation of 
the ACC/AHA Guidelines scale were significantly 
higher, and hemoglobin lower, in the clopidogrel arm. 
Comorbidities including atrial fibrillation, hyperten-
sion, cerebrovascular disease, heart failure, and di-
abetes mellitus were significantly more prevalent in 
the clopidogrel arm. Triple therapy with warfarin was 
significantly more common with patients treated with 
clopidogrel compared with patients treated with tica-
grelor. A much lower proportion of patients treated 
with clopidogrel had normal left ventricular function.
Table S3 illustrates Cox proportional hazard predic-
tors of major bleeding (PLATO and BARC 3– 5), subse-
quent MI, stroke, and mortality at 1 year.
Bleeding Outcomes
1194 International Classification of Diseases, Tenth 
Edition (ICD- 10) codes for bleeding/anemia were iden-
tified from hospital episode statistics (HES) admitted 
patient care in the 5116 participants. Bleeding events 
occurred in 11 UK healthcare institutions. Medical 
notes were interrogated for all cases with 100% follow-
 up achieved. After the initial predefined screening pro-
cess, a total of 284 patient adjudication packs were 
produced. Figure 2 outlines the process of study out-
come derivation.
Adjudication resulted in 213 confirmed major bleeding 
events (by either BARC or PLATO criteria). Agreement 
between adjudicators was acceptable (Cohen’s 
Κ=0.69 for BARC 3– 5, 0.65 for PLATO major).
Table 2 and Figures S3 and S4 illustrate rates and 
temporal nature of bleeding according to definition and 
P2Y12 inhibitor. Bleeding rates were similar (see Figure 3), 
although, after adjustment for comorbidities and patient 
demographics, there was a trend to increased PLATO 
major bleeding in the ticagrelor cohort (HR, 1.30; 95% 
CI, 0.98– 1.74; P=0.07). However, after excluding patients 
Figure 1. Flowchart of final population.
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Table 1. Patient Characteristics
All Patients (n=5116) Clopidogrel (n=2491) Ticagrelor (n=2625) P Value
Age, y 68 (57, 78) 70 (59, 80) 66 (56, 75) <0.001
Female sex 1732 (33.9) 936 (37.6) 796 (30.3) <0.001
eGFR (ml/min/1.73m2) 72.6 (56.7, 88.3) 68.4 (51.6, 84.4) 76.4 (62.1, 91.5) <0.001
eGFR <15 33 (0.7) 26 (1.0) 7 (0.3) <0.001
eGFR 15– 29 175 (3.4) 115 (4.6) 60 (2.3) <0.001
eGFR 30– 44 476 (9.3) 298 (12.0) 178 (6.8) <0.001
eGFR 45– 59 789 (15.4) 448 (18.0) 341 (13.0) <0.001
eGFR ≥60 3643 (71.2) 1604 (64.4) 2039 (77.7) <0.001
Moderate CYP3A4 inhibitors 259 (5.1) 198 (8.0) 61 (2.3) <0.001
Strong CYP3A4 inhibitors 3 (0.1) 1 (0.1) 2 (0.1) >0.99
Hemoglobin g/L, (iq range) 138 (124, 150) 136 (121, 149) 140 (127, 151) <0.001
Low hemoglobin* 1399 (27.4) 788 (31.6) 611 (23.3) <0.001
CRUSADE score 27 (19, 38) 29 (21, 40) 25 (18, 34) <0.001
CRUSADE score >40 982 (19.2) 594 (23.9) 388 (14.8) <0.001
Atrial fibrillation 232 (4.5) 156 (6.3) 76 (2.9) <0.001
Previous acute myocardial 
infarction
1112 (21.7) 566 (22.7) 546 (20.8) 0.10
Previous angina 1328 (26.0) 695 (27.9) 633 (24.1) 0.002
Hypertension 2438 (47.7) 1275 (51.2) 1163 (44.3) <0.001
Hypercholesterolemia 1719 (33.6) 829 (33.3) 890 (33.9) 0.64
Peripheral vascular disease 281 (5.5) 134 (5.4) 147 (5.6) 0.73
Cerebrovascular disease 402 (7.9) 236 (9.5) 166 (6.3) <0.001
Heart failure 252 (4.9) 143 (5.7) 109 (4.2) 0.009
Previous PCI 556 (10.9) 256 (10.3) 300 (11.4) 0.19
Previous CABG 349 (6.8) 175 (7.0) 174 (6.6) 0.57
Diabetes mellitus 1171 (22.9) 577 (23.2) 594 (22.6) 0.65
PCI for index ACS 2019 (39.5) 862 (34.6) 1157 (44.1) <0.001
CABG for index ACS 652 (12.7) 278 (11.2) 374 (14.3) <0.001
Aspirin 4996 (97.7) 2389 (95.9) 2607 (99.3) <0.001
Warfarin 139 (2.7) 95 (3.8) 44 (1.7) <0.001
Direct oral anticoagulant 3 (0.1) 0 (0) 3 (0.1) 0.25
Left ventricular function
Normal 2401 (46.9) 1113 (44.7) 1288 (49.1) 0.002
Mild impairment 299 (5.8) 135 (5.4) 164 (6.3) 0.21
Moderate impairment 852 (16.7) 435 (17.5) 417 (15.9) 0.13
Severe impairment 482 (9.4) 267 (10.7) 215 (8.2) 0.002
Unknown 1082 (21.2) 541 (21.7) 541 (20.6) 0.33
ECG changes
ST depression 1066 (20.8) 526 (21.1) 540 (20.6) 0.63
T wave inversion 1421 (27.8) 641 (25.7) 780 (29.7) 0.002
Q waves 21 (0.4) 11 (0.4) 10 (0.4) 0.74
Bundle branch block 227 (4.4) 128 (5.1) 99 (3.8) 0.02
ST- segment– elevation 718 (14.0) 358 (14.4) 360 (13.7) 0.50
Combination of above 391 (7.6) 251 (10.1) 140 (5.3) <0.001
Paced 6 (0.1) 5 (0.2) 1 (0.1) 0.12
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who underwent CABG, major bleeding at 1 year by both 
BARC and PLATO criteria was significantly increased in 
the ticagrelor cohort at 1 year (Table 3).
Subsequent Myocardial Infarction to 
1 Year
There were 326 patients with I21 or I22 (acute MI or sub-
sequent MI within 4 weeks of previous MI) as first position 
ICD- 10 codes identified in HES, after a blanking window 
of 48 hours from index event date. After interrogation of 
the medical notes from 12 different English healthcare in-
stitutions, 209 adjudication packs were produced. There 
was only 1 case where the medical notes could not be 
obtained (99.7% follow- up). The remaining 116 HES ad-
missions with MI codes not put forward for adjudica-
tion were excluded because they represented duplicate 
codes, principally that of the index MI admission.
After adjudication there were 183 (3.6%) con-
firmed MI (type 1 or 2) events. Agreement between 
adjudicators was moderate for type 1 MI (Κ=0.6). A 
small number of events (second occurrence in same 
patient) were removed for the time to first event 
analysis.
A total of 168 patients suffered any MI, repre-
senting 3.3% of the study population. There was 
no difference in the unadjusted (HR, 1.00; 95% CI, 
0.73– 1.37; P>0.99) or adjusted (HR, 1.20; 95% CI, 
0.87– 1.64; P=0.27) subsequent MI rate for patients 
treated with ticagrelor compared with patients 
treated with clopidogrel, by means of Cox propor-
tional hazard adjustment (Table 2, Figure 3). In pa-
tients who were revascularized the subsequent MI 
rate did not differ between those treated with tica-
grelor and those treated with clopidogrel (adjusted 
HR, 1.02; 95% CI, 0.63– 1.64; P=0.95). In patients 
who were medically treated there was also no sig-
nificant difference but a trend toward lower subse-
quent MI with clopidogrel (adjusted HR, 1.53; 95% 
CI, 1.00– 2.34; P=0.051).
Stroke
There were 94 HES admissions identified containing 
the prespecified stroke ICD- 10 codes. Eight duplicate 
All Patients (n=5116) Clopidogrel (n=2491) Ticagrelor (n=2625) P Value
Admitting hospital
Hospital A 997 (19.5) 551 (22.1) 446 (17.0) <0.001
Hospital B 1000 (19.6) 519 (20.8) 481 (18.3) 0.02
Hospital C 821 (16.1) 336 (13.5) 485 (18.5) <0.001
Hospital D 1167 (22.8) 525 (21.1) 642 (24.5) 0.004
Hospital E 1131 (22.1) 560 (22.5) 571 (21.8) 0.53
ACS indicates acute coronary syndrome; CABG, coronary artery bypass graft; CRUSADE, Can Rapid Risk Stratification of Unstable Angina Patients 
Suppress Adverse Outcomes With Early Implementation of the American College of Cardiology/American Heart Association Guidelines; CYP3A4, cytochrome 
P450 3A4; eGFR, estimated glomerular function rate; and PCI, percutaneous coronary intervention. *low Hb<118g/L (women), <133g/L (men).
Table 1. Continued
Figure 2. Flowchart of outcome derivation of subsequent myocardial infarction and bleeding events to 1 year.
^Hospital episode statistics; *Prespecified criteria and duplications. ACS indicates acute coronary syndrome; BARC, Bleeding 
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codes and 8 second events in the same patients were 
removed, leaving a total of 78 stroke events in the time 
to first event analysis. This represents 1.5% of the pa-
tients in the cohort suffering a stroke in the 12- month 
follow- up period. The unadjusted total (hemorrhagic 
and ischemic) stroke rate was significantly greater with 
clopidogrel than ticagrelor (2.2% versus 1.3%, P=0.02) 
but not after adjustment (Table 2, Figure 3). These find-
ings were confirmed in the propensity matched popu-
lation. (Table S4).
Mortality
Table 2 and Figure 3 demonstrate the unadjusted and 
adjusted mortality for the clopidogrel and ticagrelor 
arms. After adjustment both by Cox proportional haz-
ards modeling or by propensity score (Table S4) there 
was no difference in mortality at 12 months.
Propensity Matching
We tested the robustness of our analysis by performing 
additional propensity analysis. A total of 1954 match-
ing pairs were selected (n=3908). Table S4 details the 
matched pairs in terms of demographics and comor-
bidities. Figure S1 illustrates dot plots of standardized 
mean differences in the clopidogrel and ticagrelor 
treatments in covariates, before and after matching. 
Figure S2 illustrates degree of matching of covariates, 
by P2Y12 inhibitor, by a mirrored histogram. Figures S3 
through S7 illustrates propensity matched Kaplan- 
Meier curves for bleeding, mortality, and subsequent 
MI and supports the results using Cox proportional 
hazards modelling.
Outcomes in Patients Revascularized 
Compared With Those on Medical 
Therapy Alone
Figures S8 and S9 illustrates outcomes according to 
whether coronary intervention took place, revascu-
larization (PCI or CABG) versus no coronary revascu-
larization. The principal finding in this categorization 
was the increased incidence of crude and adjusted 
PLATO major bleeding with ticagrelor in those treated 
medically. There was also evidence of increased 
bleeding after adjustment for BARC 3 to 5 bleed-
ing. There was a signal for an increased incidence 
of MI with ticagrelor (adjusted HR, 1.53; 95% CI, 
0.99– 2.34; P=0.05). For those patients undergoing 
revascularization there was no signal for increased 
Table 2. Primary and Secondary Outcome Rates (Unadjusted)
All Patients (n=5116) Clopidogrel (n=2491) Ticagrelor (n=2625) P Value
Primary bleeding outcomes at 12 mo
BARC major bleeding, 
n (%)
165 (3.7) 80 (3.7) 85 (3.7) >0.99
BARC 3a 76 (1.8) 42 (2.0) 34 (1.5) 0.23
BARC 3b 50 (1.1) 18 (0.8) 32 (1.4) 0.08
BARC 3c 11 (0.3) 5 (0.2) 6 (0.3) 0.85
BARC 4 28 (0.6) 15 (0.7) 13 (0.5) 0.59
BARC 5 18 (0.4) 8 (0.4) 10 (0.4) 0.73
PLATO major bleeding, 
n (%)
193 (4.3) 90 (4.2) 103 (4.5) 0.61
PLATO fatal/life- 
threatening bleeding
101 (2.3) 44 (2.0) 57 (2.5) 0.32
PLATO other major 
bleeding
92 (2.1) 46 (2.2) 46 (2.0) 0.77
Secondary outcomes at 12 mo, n (%)
Subsequent myocardial 
infarction
159 (3.7) 76 (3.7) 83 (3.8) 0.86
Type 1 myocardial 
infarction
145 (3.5) 69 (3.4) 76 (3.5) 0.83
Type 2 myocardial 
infarction
18 (1.6) 10 (0.5) 8 (0.4) 0.55
Stroke, n (%) 78 (1.7) 48 (2.2) 30 (1.3) 0.02
Ischemia or unspecified 
stroke
73 (1.6) 46 (2.1) 27 (1.1) 0.01
Hemorrhagic stroke 5 (0.1) 2 (0.1) 3 (0.1) 0.70
All- cause mortality 606 (12.9) 378 (16.3) 228 (9.5) <0.001
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bleeding but with no evidence for a reduction in MI 
or stroke either.
DISCUSSION
As far as we are aware this is the first large- scale 
multicenter study to assess the effects of potent 
antiplatelet agents in clinical practice using adjudi-
cated hard end points including internationally rec-
ognized bleeding and MI definitions. Participants 
were identified from 5 centers but readmissions for 
bleeding and MI were tracked, using HES data, to 11 
and 12 healthcare facilities respectively, throughout 
England.
Our results provide some reassurance about the 
bleeding risk of ticagrelor compared with clopido-
grel in a “real world” population. Results mirrored 
those of the PLATO study with no overall difference 
but an increase in bleeding in patients who were not 
treated with CABG. Bleeding incidence rates were 
slightly lower than estimates used for power sampling. 
However, by comparison mortality was 2.5 times 
greater in this study as compared with PLATO.3 There 
were a total of 645 deaths at 1 year (12.6%) compared 
with 905 deaths (4.9%) in the PLATO study, suggest-
ing adequate power to determine signal for all- cause 
mortality. This analysis also highlights differences 
between the PLATO clinical trial population and one 
Figure 3. Unadjusted and adjusted Cox proportional hazard ratios for primary and secondary outcomes at 12 months.
*BARC indicates Bleeding Academic Research Consortium; and **PLATO, Platelet Inhibition and Patient Outcomes.
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encountered in clinical practice. It is possible compet-
ing pathologies and noncardiac causes of mortality, 
such as solid organ cancers and cerebrovascular dis-
ease, may have blunted any potential benefit of tica-
grelor. The incidence of subsequent MI was similar to 
previous studies, both from observational2 and ran-
domized controlled trials but surprisingly lower than 
PLATO,3 which was a lower risk population. There was 
no signal of benefit in terms of crude or adjusted MI or 
in adjusted mortality. Although deaths may have been 
sufficient to grant confidence in the results, the study 
was not powered for subsequent MI. Nonetheless, 
there was no signal of benefit with ticagrelor for sub-
sequent MI.
We found a clear (both crude and adjusted) in-
crease in bleeding (PLATO major bleeding criteria) in 
patients medically treated with ticagrelor compared 
with clopidogrel. (Figure  S9) This differs from the 
PLATO study, where there was no significant dif-
ference in bleeding between clopidogrel or ticagre-
lor in the subgroup of patients who were medically 
treated.15
We used a hybrid approach, combining initial 
screening via ICD- 10 coding in HES for bleeding and 
MI, followed by detailed assessment of medical notes 
and subsequent adjudication using internationally 
accepted standardized definitions for bleeding and 
MI. It is possible that both bleeding and, less likely, 
subsequent MI were missed in HES. There is some 
evidence that bleeding can be missed using admin-
istrative data.7 However, the accuracy of clinical cod-
ing and HES data has undoubtedly improved over 
time and studies now demonstrate favorable accu-
racy when using HES data to identify cardiovascular 
outcomes in trials.16,17 Face- to- face interview or tele-
phone contact with individual consented patients, as 
is standard in randomized controlled trials, are robust 
means of ascertaining completeness of follow- up. 
However, we used a wide range of codes, not solely 
codes denoting intracerebral bleeds or upper gastro-
intestinal bleeds but also including anemia. The aim 
of this was to increase our sensitivity for identifying 
possible bleeding in HES.
One must be cautious about asserting causation in 
observational studies.18 We sought to test the robust-
ness of any association by undertaking the analyses 
both by Cox proportional hazard analysis and by a 
propensity score matched population. We also under-
took to reduce bias by central coordination of adjudi-
cation and blinding to sequence, year, and drug. The 
completeness of follow- up and the national scope of 
this study emphasize that the observational nature of 
the study is not compounded by limitations in other 
aspects. It is important to emphasize the implica-
tions in this analysis relate to the differences in clini-
cal practice to that of a clinical trial population with a 
consequent weakening of net positive outcomes. The 
results cannot refute nor do they contradict PLATO3 
or PEGASUS19 (Prevention of Cardiovascular Events 
in Patients With Prior Heart Attack Using Ticagrelor 
Compared to Placebo on a Background of Aspirin) 
outcomes.
The SWEDEHEART20 (Swedish Web- System 
for Enhancement and Development of Evidence- 
Based Care in Heart Disease Evaluated According 
to Recommended Therapies) registry was another 
large observational study that used ICD- 10 coding 
data alone for outcome event. In that study, there 
was a blanking period for 1 month applied for sub-
sequent MI that could result in missed MI, particu-
larly with regard to acute stent thrombosis, which is 
heavily weighted in frequency to the first month after 
PCI. Also, it is difficult to compare bleeding risk due 
to differences in bleeding definition between ICD- 
10 codes that related to hemorrhagic stroke, gas-
trointestinal bleeding, anemia- related bleeding, and 
other bleeding. It is not clear how many of these 
patients with admission coded bleeding would ful-
fill accepted standardized international definitions 
such as BARC or PLATO. It is noteworthy that only 
18% of events with bleeding/anemia codes fulfilled 
major bleeding definitions when assessed by expe-
rienced clinicians and an adjudication committee in 
our study. (Table S1, Figure 2). Nonetheless, our re-
sults are consistent with the SWEDEHEART study 
to the extent that there was no reduction in MI or 
stroke but differ in so far as there was no reduction 
in all- cause death.
Our results are consistent with several other stud-
ies, which were restricted to patients who were revas-
cularized, which suggested no benefit with ticagrelor 
compared to clopidogrel.21– 23
Improvements in design of stents with thinner 
struts in later generation drug eluting stents could 
blunt the benefit of a more potent antiplatelet in terms 
of reduction of acute stent thrombosis and subse-
quent MI.24
This multicenter study of clinical practice in ACS, 
with specific focus on antiplatelet therapy, has im-
plications for treatment with potent antiplatelets, 
particularly with respect to those treated medically 
(Figure  S9). Individualized treatment based on risk 
scores,25 antiplatelet testing,26 or genotyping27 for 
clopidogrel appears intuitive. However the validity of 
risk scores for both MI and bleeding outcomes in 
clinical practice is questionable; antiplatelet testing 
has been associated with mixed results26,28 and the 
largest study of genotyping clopidogrel response 
was overall negative for improving outcomes.29 
Analysis of larger registries, with common definitions 
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Limitations
There are clear limitations when comparing two drugs 
in an observational study.
Temporal changes in treatment and management 
are an important confounder to consider, and these 
remain unadjusted. However, details of the temporal 
changes in local interventional practice and treatments 
indicate that if anything patients treated with ticagre-
lor (latter years) would be more likely to be a bene-
ficiary of temporal changes in treatments rather than 
the converse.
There was a trend toward increased radial com-
pared with femoral access for PCI between 2011 
and 2015, which is likely to reduce bleeding risk 
(93.2% radial procedures in 2015 versus 79.6% in 
2011). Also, there was greater use of beating heart 
(off- pump) surgery in the latter years of this study 
(ticagrelor treated period) and this is likely to have 
reduced the risk of major bleeding. The greater use 
of second- generation drug eluting stents (79.4– 
98.2% in 2011 and 2015 respectively) in the regional 
tertiary center are also likely to have reduced the 
tendency to stent thrombosis and consequent MI, 
favoring ticagrelor. The clopidogrel cohort, as an-
ticipated, represented a "higher risk" population 
with a greater incidence of major comorbidities and 
higher average age. This was also reflected in the 
higher numbers of MINAP entries that needed to 
be screened to achieve the required numbers in the 
ticagrelor arm (Figure  1). This is likely due to sev-
eral factors, not least local prescribing practices 
whereby ticagrelor may be actively avoided in the 
elderly or high bleeding risk populations. As this 
was anticipated, we planned from the outset to em-
ploy both Cox proportional analysis and propensity 
scoring to adjust for differences in the populations. 
We acknowledge that these techniques cannot fully 
adjust for hidden confounders. Nonetheless, given 
that the differences in the populations described 
would likely favor the ticagrelor arm, we believe our 
results to be meaningful.
We did not seek to validate the ACS diagnosis on 
index admission, which triggered the original prescrip-
tion of antiplatelets. The benefit of antiplatelets will 
be blunted in the absence of plaque rupture but the 
bleeding risk remains. However, this is likely to have 
affected both clopidogrel and ticagrelor time periods. 
Furthermore, MINAP is regularly audited with particu-
lar reference to ACS diagnosis.11 The adjudicated sub-
sequent MI rate for ROBOT- ACS (The Risk of Major 
Bleeding With Novel Anti- platelets: A Comparison of 
Ticagrelor With Clopidogrel in a Real World Population 
of 5000 Patients Treated for Acute Coronary Syndrome) 
is 3.3% in the year following index presentation, which 
is broadly similar to contemporaneous randomized 
controlled trials14 and registry data.2
We had insufficient power to detect true differences 
in acute stent thrombosis, subsequent MI, or revas-
cularization. A study to detect a reduction of acute 
stent thrombosis in the first month following PCI (from 
0.48% to 0.25% using contemporary frequencies of 
acute stent thrombosis) would require recruitment of 
>18 000 patients.2
Our sample size was slightly underpowered con-
sidering the lower than expected event rate of major 
bleeds in clinical practice compared with PLATO. This 
is despite the much higher risk population. A number 
of antiplatelet studies have demonstrated a clear asso-
ciation of bleeding with age and in particular age >75.6,7 
The difference observed may be because of the use of 
different bleeding definitions in studies and alternate 
methods of outcome derivation (eg, HES data).
Although we did not measure compliance, we were 
able to analyze over 1000 patients with bleeding or MI 
codes to ascertain during hospital admission if there 
was compliance or if the antiplatelet was still being 
taken. We adjusted for this in our analysis. Compliance, 
or lack thereof, is likely to have a greater impact on 
patients treated with ticagrelor for 2 main reasons: a 
twice daily dosage schedule and a propensity to in-
duce dyspnea.30 Reversible binding to P2Y12 receptors 
with a shorter half- life implies less antiplatelet effect if 
there is partial compliance.31 Lack of compliance may 
have particularly affected patients who were medically 
treated (as there are fewer aids for compliance) in those 
not undergoing PCI. This may explain no reduction in 
MI (Figure S5).
SUMMARY
In clinical practice ticagrelor does not appear to in-
crease overall bleeding following ACS. However, com-
pared with clopidogrel, there is an increase in major 
bleeding in patients not undergoing coronary revascu-
larization. However, we could not discern any reduc-
tion in MI, stroke, or mortality at 1 year after adjustment 
for case mix.
This study underscores the differences in clinical 
practice and a clinical trial population with implica-
tions for a blunting of net benefit outcomes with potent 
antiplatelets.
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Details of follow-up, adjudication of clinical outcomes  
Follow-up 
Screening for potential outcome events 
Patient outcome events, occurring at any hospital in England (population 60 million), were 
tracked from Hospital Episode Statistics (HES), using their NHS number as a unique 
identifier.  In England, HES admitted patient care (APC) data is routinely collected for all 
patient admissions, with coding for all diagnoses (ICD-10) and procedures (OPCS-4). 31-33 
For the purposes of the primary bleeding relating outcomes, readmissions to hospital that 
contained an ICD-10 code for bleeding or anaemia in any diagnostic position were identified. 
For the main secondary outcome measure of myocardial infarction, all readmissions that 
contained an MI code in the primary diagnostic position were collected. See Table S2 for full 
list of ICD-10 codes used for each outcome event.  
 
Adjudication of clinical outcomes 
All admissions identified from HES using the relevant pre-specified ICD-10 codes were 
screened for potential major bleeds. This involved detailed review of corresponding medical 
notes by at least two independent cardiologists or physicians (LM, MM, DW, TH, MR, AE). 
If the event occurred at an institution in England other than those directly involved in the 
study, medical notes were formally requested with evidence of necessary approvals. There 
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which would not represent significant or major bleeding. Therefore, each admission was 
screened before being put forward for formal adjudication based on predetermined criteria. 
These were designed to remove events that were trivial or clearly not going to meet the 
definitions of major/significant bleeding. These criteria were: chronic anaemia which 
preceded drug commencement with no drop in haemoglobin (i.e. <2g/dL change) and no 
clinical evidence of bleeding, uncomplicated epistaxis, catheter related haematuria or 
uncomplicated access site haematoma/bleeding (‘uncomplicated’ was defined as not 
requiring intervention, no haemoglobin drop, no transfusion and no haemodynamic 
compromise).  Details of the nature of events screened out in this phase were still recorded in 
the database. For all other events, a formal anonymised adjudication pack was produced 
detailing patient history, observations, discharge summaries, haemoglobin trends, 
biochemistry, the results of any imaging such as echocardiograms, ultrasound abdomens, CT 
scans, upper and lower gastrointestinal endoscopies and other relevant investigations. 
Transfusion details (the number, dates and sequence of) were also included. Events were 
censored if P2Y12 inhibitor was stopped or not taken >14 days before bleeding event or if 
they occurred >14 days after coronary artery bypass surgery.  
There was central co-ordination of adjudication and outcomes with password protected files. 
Adjudicators were blinded to year of event and investigational drug (clopidogrel or 
ticagrelor). Random ID generation ensured time sequence was blinded. These files were sent 
simultaneously and in a blinded fashion to two experienced clinicians. Clear instructions 
were provided (together with definitions) to adjudicate bleeding events according to BARC 
3-5 bleeding and PLATO major bleeding criteria. Discrepant adjudications were scrutinised 
by a third senior clinician (consultant cardiologist or haematologist) experienced in clinical 
trial end point adjudication. An adjudication committee oversaw bleeding events with 
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A similar but separate process was undertaken for ascertainment of MI events. The medical 
notes of any admissions identified from HES APC as containing the relevant ICD-10 codes 
were screened by the research team. Any event with at least one cardiac biomarker greater 
than 99th percentile was put forward for formal independent blinded adjudication by the 
generation of adjudication packs containing all necessary Events were then adjudicated using 
the Third Universal Definition for myocardial infarction by two experienced clinicians.  
Ascertainment of stroke events was again derived from HES using the pre specified ICD-10 
codes (see supplementary materials). We considered a stroke code occurring in any 
diagnostic position in HES to be indicative of an event. Clear duplicate events were removed 
based on comparison of admission/discharge dates in HES. Stroke events were not further 
adjudicated and are reported as defined by HES codes only. 
Death was determined by tracking via the Demographics Batch Service (DBS) which is part 
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Table S1. Inclusion/Exclusion Criteria. 
Inclusion Criteria 
1. Patient commenced on clopidogrel for ACS prior to change of ACS policy at each
recruiting site, or ticagrelor for same indication afterwards.
Exclusion Criteria 
1. Patient already taking the study drug in question (clopidogrel or ticagrelor) prior to
the ACS event
2. Patients under 18 years of age
3. Patients in whom the drug is stopped during the same hospital admission due to
clinical judgement dictating that it is no longer indicated (this does not apply to
patients in whom a bleeding event is the precipitant for stopping the drug, or 
patients who die or have a bleeding event within 7 days of drug cessation- both of 
whom will be included). 
4. Patients in whom the study drug may have been switched to an alternative drug
for the same indication during the original hospital admission (assuming they to do
not meet the clauses set out in criterion 3). 
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Table S2. Bleeding, MI and Stroke codes used to screen for events in HES. 
ICD-10 CODE (ADULTS) MEANING 
BLEEDING 
D50 Iron Deficiency Anaemia 
D62 Acute posthaemorrhagic anaemia 
H356 Retinal Haemorrhage 
I60 Subarachnoid haemorrhage 
I61 Intracerebral haemorrhage 
I62 Subdural/other intracranial haemorrhage 
I850 Oesophageal Varices with bleeding 
K226 Mallory Weiss syndrome 
K25. (0,2,4,6) Gastric Ulcer with bleeding 
K26. (0,2,4,6) Duodenal Ulcer with bleeding 
K27. (0,2,4,6) Peptic Ulcer with bleeding 
K28. (0,2,4,6) Gastrojejunal ulcer with bleeding 
K290 Haemorrhagic Gastritis 
K625 Haemorrhage of anus and rectum 
K92. (0,1,2) Haematemesis/melaena/GI haemorrhage unspecified 
N93. (8,9) Other abnormal uterine and vaginal bleeding 
R04 Haemorrhage from respiratory passages 
R31 Unspecified haematuria 
R58 Haemorrhage not elsewhere classified 
S065 Traumatic subdural haemorrhage 
S066 Traumatic subarachnoid haemorrhage 
S068 Other traumatic intracranial haemorrhage 
T792 Traumatic secondary and recurrent haemorrhage 
T810 Haemorrhage and haematoma complicating a procedure, not elsewhere 
T828 Other specified complications of cardiac and vascular prosthetic devices, 
implants and grafts (haemorrhage) 
MYOCARDIAL INFARCTION 
I21 Acute MI 
I22 Subsequent MI (within 4 weeks of previous MI) 
STROKE 
I60 Subarachnoid Haemorrhage 
I61 Intracerebral Haemorrhage 
I63 Cerebral Infarction 
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Table S3. Cox proportional hazard model predictors of primary and secondary endpoints (admitting hospital was entered as a random effect in all models). 
BARC bleeding PLATO bleeding Subsequent MI Stroke Mortality 
Covariate 
HR (95% CI) p-value HR (95% CI) p-value HR (95% CI) p-value HR (95% CI) p-value HR (95% CI) p-value
1.229 (0.897, 1.683) 0.20 1.303 (0.975, 1.742) 0.07 1.196 (0.870, 1.644) 0.27 0.824 (0.516, 1.317) 0.42 0.896 (0.756, 1.063) 0.21 
1.031 (1.017, 1.045) <0.001 1.030 (1.017, 1.044) <0.001 1.025 (1.010, 1.040) <0.001 1.039 (1.017, 1.061) <0.001 1.063 (1.054, 1.072) <0.001 
- - - - 0.720 (0.603, 0.860) <0.001 
- - - 0.983 (0.972, 0.994) 0.002 - 
0.987 (0.979, 0.996) 0.003 0.984 (0.977, 0.992) <0.001 0.983 (0.975, 0.992) <0.001 - 0.993 (0.988, 0.997) 0.003 
- - - - 1.034 (1.026, 1.042) <0.001 
1.788 (1.038, 3.080) 0.04 - - - - 
- - 1.777 (1.273, 2.481) <0.001 - 1.260 (1.051, 1.511) 0.01 
- - 1.721 (1.204, 2.461) 0.003 - - 
- - - - 0.737 (0.613, 0.886) 0.001 
- - - 1.919 (1.082, 3.403) 0.03 - 
- - 2.051 (1.301, 3.232) 0.002 - 1.483 (1.166, 1.885) 0.001 
- - - - 0.608 (0.430, 0.859) 0.005 
- - 1.610 (1.158, 2.240) 0.005 - - 
1.704 (1.224, 2.373) 0.002 1.628 (1.179, 2.248) 0.003 - - - 
- - - - 1.646 (1.343, 2.018) 0.003 
1.667 (1.177, 2.360) 0.004 1.615 (1.185, 2.202) 0.002 - - 1.312 (1.094, 1.573) <0.001 















LVEF: Moderate impairment 
LVEF: Severe impairment 
ECG: ST depression 
ECG: T wave inversion 
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Table S4. Patient characteristics in propensity matched cohort. 
Clopidogrel 
(n = 1954) 
Ticagrelor 
(n = 1954) 
p-value
67 (57, 78) 67 (57, 76) 0.82 
661 (33.8) 646 (33.1) 0.60 
71.9 (57.8, 87.2) 73.0 (58.0, 87.7) 0.50 
60 (3.1) 61 (3.1) 0.91 
1 (0.1) 2 (0.1) 0.56 
138 (124, 150) 139 (126, 150) 0.23 




Moderate CYP3A4 inhibitors 




AF 71 (3.6) 69 (3.5) 0.85 
Previous AMI 418 (21.4) 397 (20.3) 0.40 
Previous Angina 502 (25.7) 484 (24.8) 0.51 
Hypertension 933 (47.8) 925 (47.3) 0.79 
Hypercholesterolaemia 678 (34.7) 679 (34.8) 0.97 
Peripheral Vascular Disease 102 (5.2) 102 (5.2) >0.99
Cerebrovascular Disease 138 (7.1) 138 (7.1) >0.99
Heart Failure 98 (5.0) 88 (4.5) 0.44
Previous PCI 217 (11.1) 197 (10.1) 0.30
Previous CABG 132 (6.8) 128 (6.6) 0.80
Diabetes 448 (22.9) 457 (23.4) 0.73
PCI for index ACS 782 (40.0) 790 (40.4) 0.78
CABG for index ACS 249 (12.7) 253 (13.0) 0.84
Aspirin 1943 (99.4) 1936 (99.1) 0.13
Warfarin 40 (2.1) 38 (1.9) 0.81
DOAC 0 (0) 1 (0.1) - 
Left ventricular function 
Mild impairment 112 (5.7) 99 (5.1) 0.36 
Moderate impairment 328 (16.8) 320 (16.4) 0.73 
Severe impairment 175 (9.0) 182 (9.3) 0.69 
ECG changes 
ST depression 414 (21.2) 394 (20.2) 0.43 
T wave inversion 545 (27.9) 549 (28.1) 0.89 
Q waves 6 (0.3) 8 (0.4) 0.59 
BBB 92 (4.7) 86 (4.4) 0.65 
ST elevation 287 (14.7) 291 (14.9) 0.86 
Combination of above 129 (6.6) 133 (6.8) 0.78 
Paced 1 (0.1) 1 (0.1) >0.99
Admitting hospital 
Hospital A 402 (20.6) 390 (20.0) 0.62 
Hospital B 362 (18.5) 374 (19.1) 0.62 
Hospital C 302 (15.5) 315 (16.1) 0.55 
Hospital D 446 (22.8) 445 (22.8) 0.97 
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Figure S1. Standardised mean differences in patient characteristics for both 
unmatched and propensity matched patient groups. 
Figure S2. Mirrored histogram chart showing distribution of propensity scores in the 
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Figure S3. Kaplan-Meier chart for freedom from major bleeding in matched groups (BARC 
3-5 criteria).
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Figure S5. Kaplan-Meier chart for freedom from subsequent MI in matched groups. 
Figure S6. Kaplan-Meier chart for freedom from stroke in matched groups. D
ow
nloaded from
 http://ahajournals.org by on A
pril 10, 2021
Figure S7. Kaplan-Meier chart for survival in matched groups. 
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